Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention A Randomized Clinical Trial

Nelly R. Mugo, MBChB, MPH; Ting Hong, MD, PhD; Connie Celum, MD, MPH; Deborah Donnell, PhD; Elizabeth A. Bukusi, MBChB, PhD; Grace John-Stewart, MD, PhD; Jonathan Wangisi, MBChB; Edwin Were, MBChB, MPH; Renee Heffron, MPH, PhD; Lynn T. Matthews, MD, MPH; Susan Morrison, MD, MPH; Kenneth Nguhe, PhD; Jared M. Baeten, MD, PhD; for the Partners PrEP Study Team

IMPORTANCE Antiretroviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunodeficiency virus (HIV) acquisition. PrEP could reduce periconception HIV risk, but the effect on pregnancy outcomes is not well defined.

OBJECTIVE To assess pregnancy incidence and outcomes among women using PrEP during the periconception period.

DESIGN, SETTING, AND PARTICIPANTS Randomized trial among 1785 HIV-serodiscordant heterosexual couples (the Partners PrEP Study) in which the female partner was HIV uninfected that demonstrated that PrEP was efficacious for HIV prevention, conducted between July 2008 and June 2013 at 9 sites in Kenya and Uganda.

INTERVENTIONS Daily oral TDF (n = 598), combination FTC+TDF (n = 566), or placebo (n = 621) through July 2011, when PrEP demonstrated efficacy for HIV prevention. Thereafter, participants continued receiving active PrEP without placebo. Pregnancy testing occurred monthly and study medication was discontinued when pregnancy was detected.

MAIN OUTCOMES AND MEASURES Pregnancy incidence, birth outcomes (live births, pregnancy loss, preterm birth, congenital anomalies), and infant growth.

RESULTS A total of 431 pregnancies occurred. Pregnancy incidence was 10.0 per 100 person-years among women assigned placebo, 11.9 among those assigned TDF (incidence difference, 1.9; 95% CI, −1.1 to 4.9 [P = .22 vs placebo]), and 8.8 among those assigned FTC+TDF (incidence difference, −1.3; 95% CI, −4.1 to 1.5 [P = .39 vs placebo]). Before discontinuation of the placebo treatment group in July 2011, the occurrence of pregnancy loss (96 of 288 pregnancies) was 42.5% for women receiving FTC+TDF compared with 32.3% for those receiving placebo (difference for FTC+TDF vs placebo, 10.2%; 95% CI, −5.3% to 25.7%; P = .16) and was 27.7% for those receiving TDF alone (difference vs placebo, −4.6%; 95% CI, −18.1% to 8.9%; P = .46). After July 2011, the frequency of pregnancy loss (52 of 143 pregnancies) was 37.5% for FTC+TDF and 36.7% for TDF alone (difference, 0.8%; 95% CI, −16.8% to 18.5%; P = .92). Occurrence of preterm birth, congenital anomalies, and growth throughout the first year of life did not differ significantly for infants born to women who received PrEP vs placebo.

CONCLUSIONS AND RELEVANCE Among HIV-serodiscordant heterosexual African couples, differences in pregnancy incidence, birth outcomes, and infant growth were not statistically different for women receiving PrEP with TDF alone or combination FTC+TDF compared with placebo at conception. Given that PrEP was discontinued when pregnancy was detected and that CIs for the birth outcomes were wide, definitive statements about the safety of PrEP in the periconception period cannot be made. These results should be discussed with HIV-uninfected women receiving PrEP who are considering becoming pregnant.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00557245


Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The Partners PrEP Study Team members are listed at the end the article.

Corresponding Author: Jared M. Baeten, MD, PhD, Department of Global Health, University of Washington, 325 Ninth Ave, Box 359927, Seattle, WA 98104 (jbaeten@uw.edu).
Antiretroviral preexposure prophylaxis (PrEP) as daily oral tenofovir disoproxil fumarate and coformulated emtricitabine/tenofovir disoproxil fumarate has been demonstrated to be efficacious for the prevention of human immunodeficiency virus (HIV) acquisition in diverse populations. PrEP could be an important component of safer conception strategies for women at risk for HIV infection, including those in HIV-serodiscordant couples (i.e., in which only one member is HIV infected), particularly if the infected partner is not eligible for antiretroviral treatment or is not willing or able to take it. Efforts to implement PrEP as a public health strategy for HIV prevention in heterosexual populations will be accompanied by PrEP exposure during conception and pregnancy, either inadvertently for women with unrecognized early pregnancy or intentionally as part of reducing HIV risk during conception, and thus understanding the safety of PrEP in the periconception period is a priority.

Tenofovir disoproxil fumarate and emtricitabine are pregnancy category B medications, with no evidence of teratogenicity in animal experiments and in observational studies of humans. However, as with most medications, few data from controlled human studies in pregnancy are available. Renal and bone toxicity are known potential adverse effects of tenofovir disoproxil fumarate in HIV-infected children and adults using tenofovir disoproxil fumarate as part of long-term combination antiretroviral treatment. Observational studies of HIV-infected women using tenofovir disoproxil fumarate compared with other antiretroviral agents during pregnancy have generally indicated safety, although some data suggest slight growth restriction in infants born to women using tenofovir disoproxil fumarate.

To date, PrEP use during conception among HIV-uninfected women has not been studied systematically, to our knowledge. Within a randomized, placebo-controlled trial of PrEP for HIV prevention among HIV-serodiscordant couples, we assessed pregnancy incidence and outcomes for HIV-uninfected women and growth and renal function during the first year of life for their infants.

Methods

Study Population and Procedures

Between July 2008 and November 2010, 4,747 heterosexual HIV-serodiscordant couples from 9 sites in Kenya and Uganda were enrolled and followed in the Partners PrEP Study, a phase 3, randomized, double-blind, placebo-controlled, 3-group trial of tenofovir disoproxil fumarate and emtricitabine/tenofovir disoproxil fumarate PrEP. Study sites were selected based on prior experience in similar research, community linkages, and linkages to HIV care providers; the design and primary safety and efficacy outcomes of the trial have been reported. Eligible couples were aged 18 years or older, were sexually active, and planned to remain in the relationship for the duration of the study. HIV-uninfected participants had normal renal, hepatic, and hematologic function and were not infected with hepatitis B. They were randomized in a 1:1:1 fashion to daily oral tenofovir disoproxil fumarate (300 mg), emtricitabine/tenofovir disoproxil fumarate (200 mg/300 mg), or placebo. At monthly follow-up visits for up to 36 months, participants received individualized adherence counseling, HIV testing, and a month’s supply of study medication. At enrollment, HIV-infected partners did not meet Kenyan or Ugandan guidelines for initiation of antiretroviral therapy (generally, CD4 counts <350 cells/μL or symptomatic HIV-1 disease) and were not receiving antiretroviral therapy; they were followed quarterly and actively referred for antiretroviral therapy initiation if they became eligible during follow-up. At each study visit, participants received a package of HIV prevention services, including risk-reduction counseling, couples counseling, and condoms.

In July 2011, the trial’s independent data and safety monitoring board recommended discontinuation of the placebo group and public report of the results due to demonstration of the efficacy and safety of PrEP for HIV prevention in the study population. In the primary analysis of HIV prevention efficacy, both tenofovir disoproxil fumarate (hazard ratio, 0.33; 95% CI, 0.19-0.56; P < .001) and emtricitabine/tenofovir disoproxil fumarate (hazard ratio, 0.25; 95% CI, 0.13-0.45; P < .001) reduced HIV incidence compared with placebo; the frequency of key safety outcomes did not differ significantly across the study groups. Retention and adherence to PrEP were high, and subset analyses demonstrated high PrEP adherence and HIV protection efficacy among women.

After July 2011, the active PrEP was continued and study participants originally assigned placebo were offered rerandomization (in a 1:1 ratio) to active PrEP. Active PrEP was provided to the study population to gain additional blinded information on the relative efficacy and safety of PrEP with tenofovir disoproxil fumarate vs emtricitabine/tenofovir disoproxil fumarate while providing PrEP to participants for a period after the trial, in accordance with international guidance regarding access to effective biomedical prevention interventions against HIV. Thus, after July 2011, all participants were receiving either tenofovir disoproxil fumarate or emtricitabine/tenofovir disoproxil fumarate in a blinded fashion for up to 12 months; follow-up concluded in December 2012, with additional follow-up thereafter of pregnant women.

Pregnancy Among HIV-Uninfected Women

The safety of PrEP in HIV-uninfected women who became pregnant was defined in the study protocol as a secondary objective of the trial (Supplement 1). At enrollment, HIV-uninfected women were not pregnant, breastfeeding, or intending to become pregnant. They were counseled on the available safety data for use of emtricitabine and tenofovir disoproxil fumarate in pregnancy and advised to use contraception. Contraceptive counseling was provided at each visit, and contraceptives (oral contraceptive pills, injectable depot medroxyprogesterone acetate, intrauterine devices, hormonal implants, and condoms) were offered on site at no cost. However, contraceptive use was not a requirement for trial participation and effective contraception was reported as being used at approximately 55% of follow-up visits.

Urinary β-human chorionic gonadotropin pregnancy tests were performed at enrollment and at each monthly visit,
study medication was discontinued in the event of pregnancy, for the duration of pregnancy and breastfeeding. Given the sensitivity of monthly pregnancy testing, the study team estimated that the duration of study medication exposure in the event of pregnancy would be approximately 6 weeks or less. Pregnant women were referred for antenatal care, were not counseled by study staff about pregnancy viability or provided any inducement for pregnancy termination, and were encouraged to breastfeed infants, in accordance with World Health Organization (WHO) guidelines. Monthly HIV testing continued throughout pregnancy and breastfeeding, and women who seroconverted to HIV received expedited HIV resistance testing and referral for immediate initiation of antiretroviral therapy. Women who seroconverted to HIV positivity were discontinued from the study.

Pregnancy data were ascertained through standardized case report forms completed through participant report and summarization of medical records, when available. For pregnancies that terminated early, data on timing and nature of pregnancy loss (spontaneous or elective) were recorded. The duration of pregnancy was estimated between the first day of the last menstrual period to the date of delivery or pregnancy loss. Live-born infants were followed up during the first year of life, with the initial visit scheduled within the first month and then quarterly. Evaluation of infants included assessment for congenital anomalies; measures of infant growth (weight, length, and head circumference), conducted quarterly; and serum creatinine level, which was measured at 2 visits within 1 month and at 3 months after birth. Because infants were not delivered in the presence of the study team and were sometimes delivered at home, birth weight was inconsistently recorded and thus not included as an outcome.

Ethical Review
The study protocol was approved by the University of Washington Human Subjects Review Committee and ethics review committees at each study site. All participants provided written informed consent in English or their local language.

Statistical Analysis
Several types of outcomes were defined: incidence of pregnancy, birth outcomes, and infant outcomes. Pregnancy incidence was defined as the number of pregnancies detected over the number of woman-years of follow-up, excluding follow-up time during pregnancy. Birth outcomes included live births, pregnancy losses, preterm births, and congenital anomalies. Infant outcomes included growth, mortality, and serum creatinine level. The 2006 WHO growth standard by age in days was used to calculate sex- and age-adjusted z scores for weight, length, and head circumference during postnatal follow-up for infants born at term; for preterm infants, preterm growth standards were used and z scores were adjusted for gestational age. Infants’ age in days was derived from computing days between date of delivery and date of each study visit.

All analyses were limited to the subset of couples in which the HIV-uninfected partner was female. The primary, prespecified analysis included data collected on incident pregnancy, birth outcomes, and follow-up of infant outcomes for pregnancies detected through discontinuation of the trial’s placebo group in July 2011; for those pregnancies, the last birth was in March 2012, with last infant follow-up occurring in February 2013. This primary, placebo-controlled analysis compared each active PrEP group (tenofovir disoproxil fumarate and combined emtricitabine/tenofovir disoproxil fumarate) separately with the placebo group. After this primary analysis was completed, an additional, post hoc analysis was conducted, comparing the effect of tenofovir disoproxil fumarate alone vs combined emtricitabine/tenofovir disoproxil fumarate PrEP on pregnancy incidence and birth outcomes. The post hoc analysis was motivated by a suggestion of a higher frequency of pregnancy losses in the emtricitabine/tenofovir disoproxil fumarate group compared with the tenofovir disoproxil fumarate–only group in the primary analysis period. The post hoc analysis included all pregnancies identified during the trial period, including those identified after July 2011, both from women initially randomized to the trial’s active groups and from those rerandomized to active PrEP from placebo. The last birth in the post hoc analysis data set occurred in June 2013.

All analyses were performed following intention-to-treat principles, with the exception that pregnancies occurring after HIV seroconversion were excluded because women were discontinued from study medication. For the period covered by the primary, prespecified analysis, a total of 7 pregnancies occurred after HIV seroconversion and were excluded: 2 among women assigned tenofovir disoproxil fumarate (1 and 18 months after HIV seroconversion) and 5 among women assigned placebo (3, 6, 6, 12, and 18 months after HIV seroconversion).

Pregnancy incidence was compared with Cox proportional hazards models, stratified by study site; women were removed from the risk set while pregnant, and Andersen-Gill modification was used to account for multiple pregnancies per woman. Logistic regression was used to test for differences between groups for birth outcomes, with generalized estimating equations used to account for multiple pregnancies. Infant mortality was compared using the Fisher exact test. To assess differences by group in standardized growth outcomes, 2-sample t tests were used; in addition, growth over time by group was compared with linear mixed-effects models, with time in study, randomization group, and their interaction as fixed effects and participant as a random effect. Missing data were rare and time points with missing data were omitted from analyses.

The design of the clinical trial was end-point driven for the primary HIV protection efficacy end point. No sample size calculations were conducted before the trial specifically for the secondary outcome of pregnancy safety because the duration of the study was to be determined by the accumulation of HIV end points.

Analyses were performed with SAS version 9.3. Statistical testing was 2-sided and P < .05 was considered statistically significant.
Preexposure Prophylaxis for HIV and Pregnancy Outcomes

Original Investigation Research

Results

Population Characteristics
Of the 4747 HIV-uninfected participants enrolled and followed in the Partners PrEP Study, 1785 (37.6%) were women, of whom 598 (33.5%), 566 (31.7%), and 621 (34.8%) were randomized to tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, and placebo groups, respectively (Table 1 and Figure 1). For these 1785 women, the median age was 33 years (interquartile range [IQR], 28-38), they had a median of 6 years of education (IQR, 3-8), and 1704 (95.5%) had ever had a child, although 262 (14.7%) had not had a child with the HIV-infected partner with whom they enrolled in the trial. Most (98.7%) were married to their HIV-infected male partner characteristics, median (IQR)

<table>
<thead>
<tr>
<th>Demographic characteristics, median (IQR)</th>
<th>Tenofovir Disoproxil Fumarate (n = 598)</th>
<th>Emtricitabine/Tenofovir Disoproxil Fumarate (n = 566)</th>
<th>Placebo (n = 621)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>32 (27-37)</td>
<td>33 (28-39)</td>
<td>33 (28-39)</td>
</tr>
<tr>
<td>Education, y</td>
<td>6 (3-8)</td>
<td>6 (3-8)</td>
<td>6 (3-8)</td>
</tr>
<tr>
<td>Using effective contraception, No. (%)</td>
<td>263 (44.0)</td>
<td>275 (48.6)</td>
<td>299 (48.1)</td>
</tr>
<tr>
<td>Married</td>
<td>587 (98.2)</td>
<td>562 (99.3)</td>
<td>612 (98.6)</td>
</tr>
<tr>
<td>No children in the partnership</td>
<td>81 (13.5)</td>
<td>88 (15.5)</td>
<td>93 (15.0)</td>
</tr>
</tbody>
</table>

Sexual behavior

<table>
<thead>
<tr>
<th>No. of sex acts in previous month, median (IQR)a</th>
<th>4 (2-7)</th>
<th>4 (2-7)</th>
<th>4 (2-8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any unprotected sex in previous month, No. (%)</td>
<td>141 (24.1)</td>
<td>121 (21.9)</td>
<td>144 (23.9)</td>
</tr>
</tbody>
</table>

HIV-infected male partner characteristics, median (IQR)

<table>
<thead>
<tr>
<th>CD4 count, cells/μL</th>
<th>453 (349-598)</th>
<th>466 (362-584)</th>
<th>451 (353-600)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma HIV RNA, log10 copies/mL</td>
<td>4.06 (3.41-4.70)</td>
<td>4.21 (3.46-4.72)</td>
<td>4.08 (3.39-4.72)</td>
</tr>
</tbody>
</table>

Follow-up
Among the 1785 women, 1781 (99.8%) completed at least 1 post-randomization visit, with retention greater than 95% throughout follow-up, and 2805 total person-years of follow-up accrued for assessment of pregnancy incidence (median, 17.0 months; IQR, 10.1-24.9). Study medication was dispensed at 92.5% of attended visits. Factoring in missed visits, other reasons for nondispensation of study medication, nonadherence to dispensed study pills (as measured by pill counts of unused study product), and censoring time during pregnancy and breastfeeding, 92.2% of follow-up time was covered by study medication. In the period after discontinuation of the placebo treatment group, an additional 1294 person-years of follow-up for assessment of incident pregnancy were accrued between the 2 PrEP groups and retention remained greater than 95% (eFigure 1 in Supplement 2).

Pregnancy Incidence and Birth Outcomes
During the primary, placebo-controlled analysis period, 288 pregnancies occurred among 267 HIV-uninfected women, at an overall pregnancy incidence of 10.3 per 100 person-years (Table 2). Pregnancy incidence did not differ significantly by randomization group: 11.9, 8.8, and 10.0 per 100 person-years in the tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, and placebo groups, respectively (incidence difference, 1.9, 95% CI, −1.1 to 4.9, P = .22 for tenofovir disoproxil fumarate vs placebo, and incidence difference, −1.3, 95% CI, −4.1 to 1.5, P = .39 for emtricitabine/tenofovir disoproxil fumarate vs placebo). One pregnancy (in the emtricitabine/tenofovir disoproxil fumarate group) occurred in a woman who had not been receiving study medication for more than 3 months because of missed visits. The median duration of gestation at pregnancy detection was 35 days (IQR, 29-45): 37 (IQR, 29-46) for tenofovir disoproxil fumarate (P = .34 vs placebo), 35 (IQR, 29-42) for emtricitabine/tenofovir disoproxil fumarate (P = .89 vs placebo), and 35 (IQR, 28-46) for placebo.

Of the 288 pregnancies, 192 (66.7%) ended in live births and 96 (33.3%) ended in pregnancy losses, including 19 induced losses. Most pregnancy losses (91.7%) occurred before 20 weeks' gestation. For the live births, 47 (24.5%) were home deliveries and 182 (94.8%) were vaginal deliveries. Eleven infants (5.7%) were born preterm (<37 weeks' gestation). There was no statistically significant association between women receiving PrEP and those receiving placebo and the occurrence of pregnancy losses (difference of proportions, −4.6%, 95% CI, −18.1% to 8.9%, P = .46 for tenofovir disoproxil fumarate vs placebo; and difference of proportions, 10.2%, 95% CI, −5.3% to 25.8%).
Pregnancies detected before discontinuation of the trial’s placebo group in July 2011. HIV-uninfected women (1785) were randomized in a 1:1:1 fashion to daily oral tenofovir disoproxil fumarate, combination emtricitabine/tenofovir disoproxil fumarate, or placebo and followed for up to 36 months, through July 2011. Cumulative retention for women is detailed: denominators indicate enrollment and numerators note those completing such follow-up. Four women contributed no follow-up: 3 randomized to tenofovir disoproxil fumarate and 1 to emtricitabine/tenofovir disoproxil fumarate. One hundred ninety-four live-born infants were followed up with scheduled visits within the first month of life and then quarterly. Per-visit retention is provided, with denominators referring to infants eligible to have attended the visit (ie, excluding infants who died) and numerators referring to infants who attended the visit.

25.7%, \( P = .16 \) for emtricitabine/tenofovir disoproxil fumarate vs placebo) or preterm births (difference of proportions, \(-5.2\%\), 95% CI, \(-13.9\%\) to 3.5\%\, \( P = .16 \) for tenofovir disoproxil fumarate vs placebo; and difference of proportions, 1.0%, 95% CI, \(-11.3\%\) to 13.3%, \( P = .85 \) for emtricitabine/tenofovir disoproxil fumarate vs placebo).

Thirteen infants (6.7% of live-born infants) were born with a total of 17 congenital anomalies, a frequency that was not statistically different across randomization groups: 7.6% in the placebo group, 4.9% in the tenofovir disoproxil fumarate group (difference in proportions, \(-2.6\%\); 95% CI, \(-12.0\%\) to 6.7%; \( P = .51 \) vs placebo), and 8.5% in the emtricitabine/tenofovir disoproxil fumarate group (difference in proportions, 0.9%; 95% CI, \(-11.1\%\) to 13.0%; \( P = .86 \) vs placebo). The details of the types of congenital anomalies are reported in Supplement 2.

In the period after the placebo treatment group was discontinued in July 2011, an additional 143 pregnancies were observed in the 2 active PrEP groups among 137 women, for an overall pregnancy incidence of 10.9 per 100 person-years in the tenofovir disoproxil fumarate group and 10.4 in the emtricitabine/tenofovir disoproxil fumarate group (incidence difference, \(-0.5\) per 100 person-years; 95% CI, \(-2.8\) to 1.8; \( P = .86 \)). Of these 143 pregnancies, 88 (61.5%) ended in live births and 52 (36.4%) ended in pregnancy losses, and data were missing from 3 pregnancies. Before July 2011, there was a higher proportion of pregnancy losses in women assigned emtricitabine/tenofovir disoproxil fumarate (42.5%; difference in proportions, 14.8%; 95% CI, 0.1% to 29.5%; \( P = .04 \)) compared with that in women assigned tenofovir disoproxil fumarate (27.7%), but the frequency of pregnancy losses in the 2 groups was 36.7%
and 37.5%, respectively, for pregnancies occurring after July 2011 (difference in proportions, 0.8%; 95% CI, −16.8% to 18.5%; P = .92) and the composite data from the entire study period were not statistically significantly different, comparing the 2 PrEP groups (difference of proportions, 9.2%; 95% CI, −1.7% to 20.1%; P = .09). The overall occurrence of prematurity was not statistically different between the PrEP groups (difference of proportions, 3.9%; 95% CI, −3.1% to 11.0%; P = .20). An additional 5 congenital anomalies, occurring in 4 infants (2 in each PrEP group), were observed in pregnancies occurring after July 2011.

Overall, for the women who became pregnant in the entire study, the median number of lifetime pregnancies was 5 (IQR, 3-6). For only 8 women (2.1%) was the pregnancy experienced during this study their first; 22 (of 365 women who had had a prior pregnancy; 6.0%) had had a previous preterm birth. Maternal pregnancy-related complications were rare during the pregnancies followed in this study, with 3 woman experiencing preeclampsia (2 in the tenofovir disoproxil fumarate group and 1 in the emtricitabine/tenofovir disoproxil fumarate group) and no reports of pregnancy-induced diabetes. For 53 of the 431 pregnancies observed in the study, the HIV-infected male partner had initiated combination antiretroviral therapy at pregnancy in the uninfected female partner: 25 in the tenofovir disoproxil fumarate group (9 before and 16 after July 2011), 22 in the emtricitabine/tenofovir disoproxil fumarate group (3 before and 19 after July 2011), and 6 in the placebo group.

### Infant Outcomes

For infants conceived during the primary analysis period, retention in follow-up during the first year of life was high and comparable across the 3 study groups (Figure 1). There were 10 infant deaths, of which 5 occurred within the first 7 days of life; 4 of these 5 perinatal deaths were associated with out-of-hospital deliveries. Of these 10 deaths, 1 infant was born to a mother who had been assigned tenofovir disoproxil fumarate (acute diarrhea, age 159 days), 5 were born to mothers assigned emtricitabine/tenofovir disoproxil fumarate (preeclampsia, age 0 and 1 day [a set of twins]; septicemia, age 2 days; bronchopneumonia, age 22 days; and complications of tri-
proxil fumarate weight-adjusted as follows: for weight, 0.03 (slope over time for adjusted growth during the entirety of follow-up, differences in growth restriction for the PrEP group compared with the placebo; difference of proportions, 4.6%; 95% CI, −7.8% to 16.9%), and 6.1% (4/66) in the placebo group.

There were no statistically significant differences in head circumference, length, or weight to suggest growth retardation for infants born to women assigned PrEP compared with placebo (Figure 2). Among 30 comparisons, 4 measures reached statistical significance (P < .05) vs placebo—tenofovir disoproxil fumarate weight-adjusted z scores at 6, 9, and 12 months and emtricitabine/tenofovir disoproxil fumarate weight-adjusted z score at 12 months—each of these indicating less growth restriction for the PrEP group compared with the placebo group. In addition, in linear mixed-effects models assessing growth during the entirety of follow-up, differences in slope over time for adjusted z scores relative to the placebo were as follows: for weight, 0.03 (P = .02) for tenofovir disoproxil fumarate and 0.06 (P < .001) for emtricitabine/tenofovir disoproxil fumarate; for length, 0.03 (P = .42) for tenofovir disoproxil fumarate and 0.07 (P = .08) for emtricitabine/tenofovir disoproxil fumarate; and for head circumference, 0.02 (P = .35) for tenofovir disoproxil fumarate and 0.07 (P = .008) for emtricitabine/tenofovir disoproxil fumarate. Thus, all models indicated no reduced rate of growth for infants born to women in the tenofovir disoproxil fumarate and emtricitabine/tenofovir disoproxil fumarate groups and slightly faster growth in some measures for those groups relative to placebo. There were no statistically significant differences in serum creatinine concentrations for infants born to women assigned PrEP vs placebo (eFigure 2 in Supplement 2).

Discussion

In a randomized, double-blind, placebo-controlled trial of PrEP that demonstrated high HIV protection in the study population of African HIV-serodiscordant couples, we assessed the effect of PrEP on pregnancy for HIV-uninfected women, finding no statistically significant adverse relationship between each PrEP randomization group of tenofovir disoproxil fumarate or emtricitabine/tenofovir disoproxil fumarate compared with placebo and pregnancy incidence, birth outcomes, or infant growth and renal function. To our knowledge, these results are the first data exploring these outcomes in a randomized trial of daily oral PrEP used in the periconception period. However, for some outcomes, including pregnancy loss, preterm birth, congenital anomalies, and infant mortality, CIs were wide, including both a null effect and potential harm, and thus definitive statements about safety of PrEP in the periconception period cannot be made.

Other data, including a recent systematic review,24 have suggested that use of tenofovir disoproxil fumarate and emtricitabine during pregnancy appears safe when used by HIV-infected women taking combination antiretroviral treatment. Data on teratogenicity related to in utero exposure to tenofovir disoproxil fumarate and emtricitabine have been reassuring, with no increase in congenital anomalies compared with the expected background rate for infants enrolled in the Antiretroviral Pregnancy Registry6 (n = 1982 and n = 1400 to date with first-trimester exposure to tenofovir disoproxil fumarate and emtricitabine, respectively) and in prospective studies of women receiving antiretroviral treatment.11 Small decreases in bone mineral density have been observed with use of tenofovir disoproxil fumarate in animal models and among adults taking tenofovir disoproxil fumarate—containing HIV treatment regimens, but several studies have not shown increased risk of growth or bone abnormalities in infants born to HIV-infected women receiving tenofovir disoproxil fumarate,22 with 1 study showing slightly smaller infant length and head circumference at 1 year, of uncertain significance.22

In a study of antiretroviral treatment conducted among HIV-infected women in Uganda and Zimbabwe (the DART study), infants exposed to tenofovir disoproxil fumarate in pregnancy compared with infants exposed to non–tenofovir disoproxil fumarate—containing treatment regimens had similar neonatal morbidity, mortality, or growth within 2 years of follow-up.16 In agreement with this body of information, WHO and US guidelines for the treatment of HIV infection in pregnant women recommend tenofovir disoproxil fumarate– and emtricitabine-containing regimens as first-line therapy.22,23 Few data have been available to assess the safety of tenofovir disoproxil fumarate and emtricitabine in pregnant women without HIV infection; the recent systematic review of tenofovir disoproxil fumarate safety in pregnancy included data from only 11 HIV-uninfected women exposed to the drug as part of treatment for hepatitis B infection.24 Although tenofovir disoproxil fumarate has been associated with renal abnormalities, including elevations in serum creatinine level and proximal renal tubular dysfunction in a minority of adults receiving tenofovir disoproxil fumarate—containing treatment regimens,9 most with preexisting renal compromise or other risk factors for renal disease, to our knowledge, no data have been published on the effect of tenofovir disoproxil fumarate exposure in utero on infant renal function. Our results, which characterized pregnancy incidence, birth outcomes, and infant growth and renal function in a randomized comparison of HIV-uninfected women who became pregnant while receiving daily oral tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, or placebo, thus substantially add to the available data regarding the use of tenofovir disoproxil fumarate and emtricitabine in early pregnancy.

The absolute frequency of pregnancy loss was higher for women receiving emtricitabine/tenofovir disoproxil fumarate than that of those assigned tenofovir disoproxil fumarate alone or placebo. Although the differences were not statistically significant, the 95% CIs compared with placebo were wide and ranged from −5.3% (protective) to 25.7% (harmful). The difference in the frequency of pregnancy loss between tenofovir disoproxil fumarate alone and emtricitabine/tenofovir disoproxil fumarate was attenuated in the data ac-
cumulated after July 2011. In post hoc analysis of the composite data for the entire study period, pregnancy loss was higher among women receiving emtricitabine/tenofovir disoproxil fumarate compared with those receiving tenofovir disoproxil fumarate alone, but the difference was not statistically significant (difference of proportions, 9.2%; 95% CI, −1.7% to 20.1%; \( P = .09 \)). Additional studies including outcomes of pregnancy in women using PrEP during the periconception period are warranted.

For more rare outcomes (eg, premature birth, congenital anomalies), only very large data sets would have substantial statistical power, particularly for specific anomalies. The Antiretroviral Pregnancy Registry has open collection of data on pregnancies with exposure to antiretroviral agents, including when used as PrEP, and the manufacturer of emtricitabine/tenofovir disoproxil fumarate is conducting a prospective observational study of women who become pregnant while using PrEP.\(^{25}\)

One-third of pregnancies detected in our study ended in pregnancy losses; this rate may be related to monthly pregnancy testing with sensitive urine \( \beta \)-human chorionic gonadotropin assays, which was performed to detect pregnancies before clinical recognition to limit fetal exposure to PrEP in the clinical trial. Previous studies of sensitive pregnancy monitoring have demonstrated that approximately 30% of pregnancies terminate early, most without clinical recognition (sometimes referred to as “chemical pregnancies”).\(^{26}\) The average duration of in utero PrEP exposure in our study was approximately 5 weeks.

In implementation of PrEP as an HIV prevention strategy for heterosexual populations, pregnancies will occur; indeed, pregnancy rates greater than 10% per year are common in women enrolled into clinical trials of novel HIV prevention strategies, even when they are counseled to avoid pregnancy during the study period.\(^{18,27-31}\) In sub-Saharan Africa, young women are the population at greatest risk for HIV acquisition and the season for highest HIV risk overlaps with periods of greatest fertility. For example, in Kenya, 65% of HIV infections in women occur before the age of 35, the peak period for childbearing.\(^{32}\) Safe and effective HIV prevention options for women that do not require negotiations for safe sex and do not interfere with conception and pregnancy outcomes are a priority. For known, mutually disclosed HIV-serodiscordant couples, such as those enrolled in this trial, becoming pregnant risks HIV transmission, and most couples worldwide do not have access to assisted reproduction options to reduce HIV risk. The desire for pregnancy among serodiscordant couples is often great and can override fear of HIV transmission associated with conception attempts.\(^{31,33-35}\) Our findings provide additional evidence to support the option of periconception administration of antiretroviral PrEP for HIV-uninfected women in both high- and low-income populations, along with other strategies such as antiretroviral treatment of their HIV-infected partners and limiting unprotected sex to peak fertility periods to reduce the risk of sexual transmission of HIV.\(^{36}\)

Our study had several important strengths. A key strength was its randomized, placebo-controlled design. Similar data are rarely available to assess medication risks when used in
early pregnancy, and recent analyses of tenofovir disoproxil fumarate use in pregnancy have called for randomized evidence. Additional strengths include the large sample size, high retention (including of infants followed for a year after birth), and high adherence to the study medication during the periconception period, as we recently reported. However, our study also had several limitations. First, our findings are limited to periconception exposure of tenofovir disoproxil fumarate and emtricitabine, with short duration of in utero exposure after conception. In a nonresearch setting, women would likely have a longer exposure after achieving pregnancy; longer durations of in utero exposure in observational cohorts of HIV-infected women suggest safety of these medications when used during pregnancy. Observational studies have suggested that pregnant women face increased risk of HIV acquisition, and additional data are needed on the safety of continuation of tenofovir disoproxil fumarate–based PrEP throughout pregnancy, including maternal and infant bone density safety after extended exposure. The US Food and Drug Administration registered a formal label indication for emtricitabine with tenofovir disoproxil fumarate as the first agent for the prevention of sexual transmission of HIV in 2012; the approved label includes consideration for continuing emtricitabine with tenofovir disoproxil fumarate PrEP in pregnant women with ongoing HIV risk. For women who breastfeed after pregnancy, limited data are available regarding excretion into breast milk and absorption by infants, and additional studies are needed. Recent comprehensive PrEP guidelines from the US Centers for Disease Control and Prevention also address use during periconception periods and pregnancy, as well as additional considerations for persons with other comorbidities (eg, chronic active hepatitis B infection, renal impairment). Second, for some rare outcomes, such as preterm births and congenital anomalies, our results had wide CIs.

Conclusions

Among HIV-serodiscordant heterosexual African couples, differences in pregnancy incidence, birth outcomes, and infant growth were not statistically significant for women receiving PrEP with tenofovir disoproxil fumarate or combination emtricitabine/tenofovir disoproxil fumarate compared with placebo. However, given that CIs for the birth outcomes were wide, definitive statements about the safety of PrEP in the periconception period cannot be made. These results should be discussed with HIV-uninfected women receiving PrEP who are considering becoming pregnant.
Additional Contributions: We thank the site teams, particularly the site clinicians who conducted the assessments of women and their infants for this analysis, and the couples who participated in this study. The study team acknowledges the Director KEMRI for support. Study medication was donated by Gilead Sciences (Foster City).

REFERENCES